Obliterative vaginal procedure for post hysterectomy vault prolapse in severe factor 7 deficiency: a case report and literature review
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20234097Keywords:
Pelvic organ prolapse-quantification, Rare bleeding, DisordersAbstract
There is a concern about perioperative bleeding with any surgical intervention in patient with congenital factor VII (FVII) deficiency. The optimum dosage regimen for recombinant activated factor VII (rFVIIa) use has been not clearly established. We report a woman with post hysterectomy vault prolapse management with congenital FVII deficiency who underwent obliterative vaginal procedure. A 50-year-women with congenital FVII deficiency was diagnosed as post hysterectomy vault prolapse and planned for partial colpocleisis. She was planned to monitor FVII activity and prothrombin time international normalized ratio (PT/NR) intraoperatively. At the start of surgery, FVII activity was 3% and PT was INR 35.3 with INR of 2.83. (0.8-1.2). Presuming the improvement of 25% activity, 5 mg (70 mcg/kg body wt.) rFVIIa was administered. The PT was improved to 28.4 sec, Surgery was successfully completed without unexpected bleeding. Post operatively there was no oozing hence FVII activity and PT-INR was not checked. An additional rFVIIa dose of 2mg was given prophylactically after 12 hours of surgery. The patient was discharged on the third day after surgery without postoperative complication. In this case, rFVIIa was used just twice and there were no bleeding events during the perioperative period. Previous reports suggested using 15-30 μg/kg of rFVIIa before surgery and subsequent every 4-6 h in the first 24 h, then increasing the interval to 8-12 h. It is necessary to evaluate optimal dose of rFVIIa based on the risk and surgical invasiveness for each case. Our patient with congenital FVII deficiency uneventfully underwent obliterative vaginal procedure.
References
Wei DC, Wong RW, Robertson EP. Congenital factor VII deficiency presenting as delayed bleeding following dental extraction. A review of the role of factor VII in coagulation. Pathology (Phila). 1997;29(2):234-7.
Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125(13):2052-61.
Wiszniewski A, Szczepanik A, Misiak A, Bykowska K, Szopiński P. Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2015;26(3):324-30.
Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-21.
Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30(6):596- 608.
Dewerchin M, Liang Z, Moons L, Carmeliet P, Castellino FJ, Collen D et al. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost. 2000;83(2):185-90.
Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost. 2001;27(4):373-84.
Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33(4):883-90.
Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood J Am Soc Hematol. 2019;133(5):415-24.
Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol. 2004;121(1):124-37.
Lee E, Burey L, Abramovitz S, Desancho MT. Management of pregnancy in women with factor VII deficiency: A case series. Haemophilia. 2020;26(4):652-6.
Szczepanik A, Wiszniewski A, Oses-Szczepanik A, Dąbrowski W, Pielaciński K, Misiak A. Surgery in patients with congenital factor VII deficiency - a single center study. Pol Przegl Chir. 2018;90(5):1-5.
Tran HTT, Tjønnfjord GE, Paus A, Holme PA. rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemoph Off J World Fed Hemoph. 2011;17(5):764-70.
Rajpurkar M, Cooper DL. Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. J Blood Med. 2018;9:227-39.
Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-800.
